CurePSP

Guidance on the process of applying for Social Security disability benefits. Thursday, February 23, 2012, 4pm - 5pm EST.

Browse clinical trial information to find studies in your area on clinicaltrials.gov.

Presented by Amie L. Peterson, MD, a neurologist with the Parkinson Center of Oregon at Oregon Health and Science University.

A recording of our latest webinar in Flash Video format.

CurePSP's diseases are now included in Social Security's Compassionate Allowance.

President-CEO Richard Gordon Zyne, DMin interviewed.

The meeting was held in Arlington, Virginia at the Crystal City Marriott on November 17. Follow the link above to read more.

Speech and Swallowing in PSP, CBD, MSA and Related Disorders, presented by Kristin Larsen, MA, CCC-SLP

October 28-29, 2011 in Dallas, Texas. Follow the link for more info!

Presented by Amy Comstock Rick, JD, CEO, Parkinson's Action Network, and Becca O'Connor, JD, Director of Government Relations.

Presented by Sandra Holten, MT-BC, NMT Fellow

CurePSP-funded Study Identifies Three New Genes Linked to Progressive Supranuclear Palsy

The goal of this trial is to test if Rifampicin will prevent progression of the disease.

The third issue of Because Hope Matters, our bi-monthly newsletter, is now available for viewing.

Our recent webinar presented by Chaplain David Wenker, of Penn Hospice at Rittenhouse.

The second issue of Because Hope Matters, our bi-monthly newsletter, is now available for viewing.

On February 8, 2011, Dr. Bruce Morimoto, Vice President of Drug Development for Allon Therapeutics, presented an update on the davunetide study.

An international advocacy day to bring widespread recognition of rare diseases as a global health challenge.

On Oct. 18, 2010, Dr. Irene Litvan gave a webinar on the challenges of managing CBD.

The first issue of Because Hope Matters, our bi-monthly newsletter, is now available for viewing.

Thursday, January 13, 2011, 2:00pm - 3:00pm EST

Dr. Irene Litvan, of the University of Louisville, is conducting a study that will determine the role of specific risk factors in the development of PSP.

The Department of Neurology at UCLA School of medicine is currently conducting a research study under the direction of Allan D. Wu, M.D. and Choi Deblieck, Ph.D.